Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has received a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.
Several equities analysts recently issued reports on the company. Stifel Nicolaus started coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th.
Check Out Our Latest Analysis on Pyxis Oncology
Institutional Trading of Pyxis Oncology
Pyxis Oncology Price Performance
Shares of Pyxis Oncology stock opened at $3.61 on Thursday. The stock has a market capitalization of $212.59 million, a P/E ratio of -2.65 and a beta of 1.27. The business has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $3.74. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current fiscal year.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Read More
- Five stocks we like better than Pyxis Oncology
- Consumer Discretionary Stocks Explained
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Find Undervalued Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Are the FAANG Stocks and Are They Good Investments?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.